Additional file 2: Figure S2. of Phase 1b randomized, double-blind study of namilumab, an anti-granulocyte macrophage colony-stimulating factor monoclonal antibody, in mild-to-moderate rheumatoid arthritis

Huizinga, T.; Batalov, A.; Stoilov, R.; Lloyd, E.; Wagner, T.; Saurigny, D.; Souberbielle, B.; Esfandiari, E.

doi:10.6084/m9.figshare.c.3712711_D2.v1

13075_2017_1267_MOESM2_ESM.pdf (16.66 kB)

Additional file 2: Figure S2. of Phase 1b randomized, double-blind study of namilumab, an anti-granulocyte macrophage colony-stimulating factor monoclonal antibody, in mild-to-moderate rheumatoid arthritis

journal contribution

posted on 2017-03-09, 05:00 authored by T. Huizinga, A. Batalov, R. Stoilov, E. Lloyd, T. Wagner, D. Saurigny, B. Souberbielle, E. Esfandiari

Flow diagram showing patient disposition. DMARDs disease-modifying antirheumatic drugs, HIV human immunodeficiency virus, IgG, immunoglobulin G (PDF 16 kb)

Funding

Takeda Pharmaceutical Company

History

Usage metrics

Read the peer-reviewed publication

Phase 1b randomized, double-blind study of namilumab, an anti-granulocyte macrophage colony-stimulating factor monoclonal antibody, in mild-to-moderate rheumatoid arthritis

Arthritis Research & Therapy

Keywords

GM-CSF Namilumab Phase 1b Rheumatoid arthritis

Licence

CC BY + CC0

Additional file 2: Figure S2. of Phase 1b randomized, double-blind study of namilumab, an anti-granulocyte macrophage colony-stimulating factor monoclonal antibody, in mild-to-moderate rheumatoid arthritis

Funding

Takeda Pharmaceutical Company

History

Usage metrics

Read the peer-reviewed publication

Categories

Keywords

Licence

Exports